|
cluster analysis |
8 |
|
early intervention |
8 |
|
employment |
8 |
|
long-term outcomes |
8 |
|
schizophrenia |
8 |
|
adolescent |
6 |
|
adult |
6 |
|
aged |
6 |
|
alcohol drinking |
6 |
|
alcohols |
6 |
|
alpha fetoprotein blood level |
6 |
|
cancer adjuvant therapy |
6 |
|
depressive symptoms |
6 |
|
environment-wide association study |
6 |
|
mental well-being |
6 |
|
moderate drinkers |
6 |
|
physical well-being |
6 |
|
social well-being |
6 |
|
myelofibrosis |
5 |
|
neutropenia |
5 |
|
next-generation sequencing |
5 |
|
primary |
5 |
|
prognosis |
5 |
|
secondary |
5 |
|
cancer outcomes |
4 |
|
cancer site-standardized relative survival |
4 |
|
global health |
4 |
|
health economics |
4 |
|
acquired immune deficiency syndrome |
3 |
|
cancers |
3 |
|
cervical cancer |
3 |
|
china |
3 |
|
cobas |
3 |
|
condom |
3 |
|
enterobacteriaceae |
3 |
|
heterosexuality |
3 |
|
hpv test |
3 |
|
human immunodeficiency virus infection |
3 |
|
infection |
3 |
|
mendelian randomization |
3 |
|
neutropenic fever |
3 |
|
onclarity |
3 |
|
primary screening |
3 |
|
reporting guideline |
3 |
|
reporting quality |
3 |
|
systematic review |
3 |
|
bias-correction |
2 |
|
block-diagonal |
2 |
|
classification |
2 |
|
epidermal growth factor receptor mutation |
2 |
|
gene expression |
2 |
|
gene-environment interaction |
2 |
|
high-dimensional data |
2 |
|
linear discriminant analysis |
2 |
|
lung adenocarcinoma |
2 |
|
lung cancer |
2 |
|
never-smokers |
2 |
|
non-small cell lung cancer |
2 |
|
predictive models |
2 |
|
prognostic models |
2 |
|
radio frequency |
2 |
|
single nucleotide polymorphisms |
2 |
|
sociology |
2 |
|
statistics |
2 |
|
survival |
2 |
|
vegetation |
2 |
|
adaptive design |
1 |
|
advanced cancer |
1 |
|
adverse events |
1 |
|
adverse events related to age |
1 |
|
animals |
1 |
|
balance of covariates distribution |
1 |
|
biomarker |
1 |
|
blood |
1 |
|
calgb |
1 |
|
case-control studies |
1 |
|
cells, cultured |
1 |
|
cetuximab |
1 |
|
chemotherapy |
1 |
|
clinical trial |
1 |
|
colorectal cancer |
1 |
|
combined modality therapy |
1 |
|
dose finding |
1 |
|
doses |
1 |
|
eortc |
1 |
|
everolimus |
1 |
|
extensive-stage small cell lung cancer |
1 |
|
female |
1 |
|
ganitumab |
1 |
|
gaussian process |
1 |
|
gene expression regulation |
1 |
|
geriatric oncology |
1 |
|
hedgehog proteins/*genetics/metabolism |
1 |
|
human |
1 |
|
humans |
1 |
|
hypothyroidism/*etiology/metabolism |
1 |
|
kaplan–meier curve |
1 |
|
liver regeneration/*physiology |
1 |
|
liver/*metabolism/pathology |
1 |
|
maintenance chemotherapy |
1 |
|
male |
1 |
|
maleneoplasm |
1 |
|
marginal likelihood |
1 |
|
marginal treatment effect |
1 |
|
mesothelioma |
1 |
|
meta-analysis |
1 |
|
mice |
1 |
|
mice, inbred c57bl |
1 |
|
mice, transgenic |
1 |
|
mixed model |
1 |
|
non-alcoholic fatty liver disease/genetics/metabolism/physiopathology |
1 |
|
observational study |
1 |
|
older patients |
1 |
|
panitumumab |
1 |
|
pathology |
1 |
|
pathway based analysis |
1 |
|
phase i |
1 |
|
plasma |
1 |
|
prebiotics |
1 |
|
probiotics |
1 |
|
proof of concept |
1 |
|
prophylactic cranial irradiation |
1 |
|
rats |
1 |
|
rats, sprague-dawley |
1 |
|
respiratory tract infections |
1 |
|
seamless design |
1 |
|
signal transduction/genetics |
1 |
|
small cell lung cancer |
1 |
|
stromal cells/*metabolism/pathology |
1 |
|
subsets of covariates |
1 |
|
sunitinib |
1 |
|
synbiotics |
1 |
|
thoracic radiation therapy |
1 |
|
thyroid hormones/metabolism |
1 |
|
toxicity |
1 |
|
unknown link |
1 |
|
utility |
1 |
|
wound healing/physiology |
1 |
